GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (XTER:HPHA) » Definitions » YoY EPS Growth

Heidelberg Pharma AG (XTER:HPHA) YoY EPS Growth : 55.00% (As of May. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Heidelberg Pharma AG YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Heidelberg Pharma AG's YoY EPS Growth for the quarter that ended in May. 2024 was 55.00%.

Heidelberg Pharma AG's Earnings per Share (Diluted) for the three months ended in May. 2024 was €-0.09.


Heidelberg Pharma AG YoY EPS Growth Historical Data

The historical data trend for Heidelberg Pharma AG's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG YoY EPS Growth Chart

Heidelberg Pharma AG Annual Data
Trend Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.20 -69.44 -31.15 33.75 16.98

Heidelberg Pharma AG Quarterly Data
Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -400.00 100.00 28.57 28.57 55.00

Heidelberg Pharma AG YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Heidelberg Pharma AG's YoY EPS Growth for the fiscal year that ended in Nov. 2023 is calculated as:

YoY EPS Growth (A: Nov. 2023 )
=(Earnings per Share (Diluted) (A: Nov. 2023 )-Earnings per Share (Diluted) (A: Nov. 2022 ))/ | Earnings per Share (Diluted) (A: Nov. 2022 ) |
=(-0.44--0.53)/ | -0.53 |
=16.98 %

Heidelberg Pharma AG's YoY EPS Growth for the quarter that ended in May. 2024 is calculated as:

YoY EPS Growth (Q: May. 2024 )
=(Earnings per Share (Diluted) (Q: May. 2024 )-Earnings per Share (Diluted) (Q: May. 2023 )) / | Earnings per Share (Diluted) (Q: May. 2023 )) |
=(-0.09--0.2)/ | -0.2 |
=55.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Heidelberg Pharma AG YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Heidelberg Pharma AG Business Description

Traded in Other Exchanges
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Executives
Prof. Dr. Andreas Pahl Board of Directors

Heidelberg Pharma AG Headlines

No Headlines